Diarrhea News and Research

Latest Diarrhea News and Research

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Improper food handling can lead to gastrointestinal illness in children

In the confined space of a classroom, gastrointestinal illnesses can spread quickly, causing sufferers many painful and uncomfortable symptoms. But what is to blame for a school-based outbreak? In most cases, improper food handling is the culprit, says a Ryerson University public health expert.

28 Jan 2011

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.

28 Jan 2011

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

28 Jan 2011

Lancet series examines health issues facing populations in Southeast Asia

"Southeast Asia's 600 million people are facing a raft of new health challenges as the disaster-prone region undergoes some of the world's fastest social change," according to a series of papers and commentary pieces, published Tuesday in the Lancet, Agence France-Presse reports (O'Brien, 1/25).

27 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Wrigley launches school-based program to improve health, nutrition in school-age children

The Wm. Wrigley Jr. Company Foundation today announced the launch of a two-year, $3 million school health partnership with Save the Children. The initiative will be activated in six countries across the world, aimed at improving the health and nutrition of more than 273,000 school-age children in disadvantaged communities.

25 Jan 2011

PediatRx announces first-ever revenues and successful launch of GRANISOL

PediatRx Inc.is pleased to provide an update on activities for the fiscal third quarter. Among its achievements, the hospital specialty pharmaceutical company reported its first-ever revenues and successfully launched GRANISOL™, the company's first commercial entry.

24 Jan 2011

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

Furiex Pharmaceuticals, Inc. today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

24 Jan 2011

FDA accepts Optimer's fidaxomicin NDA for filing

Optimer Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI.

24 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Rotavirus vaccine significantly cuts child hospitalizations, study says

Developing and developed countries that require children to be vaccinated against rotavirus "have significantly reduced the number of children admitted to hospitals with the disease, a report showed on Thursday," Reuters reports (Kelland, 1/20).

24 Jan 2011

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

24 Jan 2011

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

A latest study has shown that the rotavirus vaccines have helped drastically reduce hospital visits around the world. Rotavirus can lead to fatal cases of diarrhea in children and causes half a million deaths in kids under five each year around the world. Developing countries are particularly at risk.

20 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

20 Jan 2011

Legionnaires’ disease scare in Bali: Australian tourists warned

Commonwealth chief medical officer Jim Bishop has warned Australians who have returned from Bali on an outbreak of Legionnaires’ disease on the popular Indonesian resort island. The Australian health authorities knew of 11 cases of Legionnaires’ disease detected in Victorians and Western Australians after holidays in the Kuta area of Bali between August 2010 and January 2011.

19 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Improper food handling can lead to gastrointestinal illness in children

CSL Behring receives marketing approval for HAE drug Berinert in Israel

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Lancet series examines health issues facing populations in Southeast Asia

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Wrigley launches school-based program to improve health, nutrition in school-age children

PediatRx announces first-ever revenues and successful launch of GRANISOL

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

FDA accepts Optimer's fidaxomicin NDA for filing

FDA approves Clinical Data's Viibryd for major depressive disorder

Rotavirus vaccine significantly cuts child hospitalizations, study says

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients

Legionnaires’ disease scare in Bali: Australian tourists warned

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in